Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It

Vertex Pharmaceuticals has built the NaV1.8 market and is now positioned to profit from it. Latigo, a biotechnology company, may be the one to benefit from Vertex's work, as it has a similar drug in development.

This development could have significant implications for the treatment of chronic pain, as both companies' drugs target the NaV1.8 sodium channel.